The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Letter to the Editor October 15, 2008

Association of Chronic Fatigue Syndrome and Acute Psychotic Episode: Is It Coincidental?

Charles Kornreich, M.D.; Maya Szombat, M.D.; Yun-Marie Vandriette, M.D.; Bernard Dan, M.D.

Prim Care Companion J Clin Psychiatry 2008;10(5):412-412

Article Abstract

Letter to the Editor

Association of Chronic Fatigue Syndrome and Acute Psychotic Episode: Is It Coincidental?

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 26 • 2024 • Number 6

Read the Current Issue

Narrative Review

Dextromethorphan-Quinidine for Agitation in Dementia

Original Research

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Original Research

Intervention to Enhance Mental Health Competency

Original Research

Evolution of Treatment Modalities for PTSD

Rounds in the General Hospital

Etiology, Prevention, and Management of TD

Rounds in the General Hospital

Comorbid Bipolar Disorder and PTSD

View current Issue

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu, Hiroyoshi Takeuchi

Asenapine, Aggression, and Affinity

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet, André Gillibert, Barbara Mintzes, et al